# Negev Capital

Negev Capital is a Venture Capital based in Grand Cayman, Cayman Islands.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Grand Cayman, Cayman Islands
- **Region:** Americas
- **Address:** Grand Cayman, Cayman Islands
- **Founded:** 2021
- **Assets under management:** Undisclosed
- **Website:** www.negevcap.com
- **LinkedIn:** https://www.linkedin.com/company/negev-capital

## Regulatory record

- **Reports private funds:** No

## About

Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of development. They aim to support those early-stage companies in need of capital that promote the thoughtful, responsible, medical use of psychedelic medication for psychiatric disorders, and who have excellent management and science teams, and solid IP.

## Sectors

- Biotech
- Healthcare Services

## Questions

### What therapeutic areas does Negev Capital target?

Negev Capital is exclusively dedicated to central nervous system and brain health therapeutics. The firm invests in biotech companies developing treatments for neurological and psychiatric conditions. This singular focus sets it apart from generalist life sciences investors who spread capital across oncology, rare disease, and other broader categories.

### Which large pharmaceutical companies have acquired Negev Capital portfolio companies?

Publicly disclosed exits from the Negev Capital portfolio include acquisitions by AbbVie and Otsuka. AbbVie is a major biopharmaceutical company with significant neuroscience operations, while Otsuka is a Japanese pharmaceutical firm with a leading franchise in CNS and psychiatric medicine. These exits validate the fund's thesis that large pharma will pay a premium for de-risked CNS assets.

### What stage of company does Negev Capital invest in?

Negev Capital invests at the early stage, spanning both seed and startup phases of company formation. The firm does not publicly detail whether these are drug-discovery targets or assets that have reached pre-clinical proof of concept. The strategy ultimately aims to hold positions until they become attractive to strategic acquirers.

## Related profiles

- [Negen Capital](https://altss.com/profile/negen-capital-services)
- [Nehemiah Community Reinvestment Fund](https://altss.com/profile/nehemiah-community-reinvestment-fund)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/negev-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology